An Audit to Evaluate the Clinical Safety and PSA Response of Firmagon® (Degarelix) in Patients with Advanced Metastatic Prostate Cancer -. Journal of Cancer Research Updates, [S. l.], v. 2, n. 1, p.  21–25, 2013. DOI: 10.6000/1929-2279.2013.02.01.4. Disponível em: https://www.neoplasiaresearch.com/index.php/jcru/article/view/398. Acesso em: 9 may. 2026.